|
Nov 13
|
Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise
|
|
Nov 13
|
Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock
|
|
Nov 13
|
With 86% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing
|
|
Nov 10
|
AstraZeneca PLC (NASDAQ:AZN) Q3 2023 Earnings Call Transcript
|
|
Nov 10
|
AstraZeneca prioritizes US for RSV drug amid surge in cases
|
|
Nov 10
|
Weight-loss drug maker to spend £4.9bn on new facilities amid surging demand
|
|
Nov 10
|
AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate
|
|
Nov 10
|
AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View
|
|
Nov 10
|
PRESS DIGEST-British Business - Nov. 10
|
|
Nov 9
|
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
|
|
Nov 9
|
Medicare drug price negotiations: AstraZeneca CEO's take
|
|
Nov 9
|
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
|
|
Nov 9
|
The battle for weight loss drug dominance is heating up. Here's why.
|
|
Nov 9
|
Petrol garages under fire over rising margins at the pump
|
|
Nov 9
|
AstraZeneca bets on weight-loss pill to compete with wave of new ‘miracle’ jabs
|
|
Nov 9
|
AstraZeneca Strikes a Deal for an Experimental Weight-Loss Drug and Boosts Its Guidance
|
|
Nov 9
|
AstraZeneca CFO: Obesity Market Has a Lot of Potential
|
|
Nov 9
|
Jobless Claims Decreased More Than Expected
|
|
Nov 9
|
AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost.
|
|
Nov 9
|
Pre-Markets Strong on Higher Bond Rates, Mixed Earnings
|